NEW YORK (GenomeWeb) – Bristol-Myers Squibb and GeneCentric Diagnostics are working together to explore whether GeneCentric's Cancer Subtype Platform can identify translational biomarkers for BMS's cancer immunotherapy Opdivo (nivolumab).

GeneCentric said it has also secured equity funding from BMS that will support the clinical development of its CSP and the build-out of its new laboratory in North Carolina's Research Triangle Park. It didn't disclose the amount of that investment, however.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Berkeley researchers have engineered yeast to make the molecule behind the hoppy taste of beer, Quartz reports.

King's College London researchers examine the influence of school type and genetics on academic achievement.

FiveThirtyEight writes that most who take a direct-to-consumer BRCA1/2 genetic test won't learn much from it.

In Science this week: early life experience influence somatic variation in the genome, and more.